Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

RTTNews | 509 दिनों पहले
Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy

(RTTNews) - Pharmaceutical companies Astellas Pharma Inc. (ALPMY.PK) and Poseida Therapeutics, Inc. (PSTX) announced Monday a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy.

Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8.3 million shares of common stock of Poseida or approximately 8.8% of the outstanding common stock of Poseida, at $3.00 per share in a private placement.

It will also make a one-time $25 million payment for a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs: P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.

In addition, Poseida has granted Astellas a board observer seat, which includes the ability to attend Poseida's scientific advisory board meetings, and certain notice rights related to any potential change of control of Poseida.

read more
Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of XTANDI (enzalutamide) as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
RTTNews | 281 दिनों पहले
Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints

Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. (SGEN) and Astellas Pharma Inc. (ALPMY.PK, ALPMY).
RTTNews | 463 दिनों पहले
TSX Ends Modestly Lower

TSX Ends Modestly Lower

https://money.tmx.com/canadian-markets https://www.rttnews.com/3499633/bay-street-likely-to-open-slightly-higher.aspx?type=cn
RTTNews | 1 दिन पहले
U.S. Stocks Close Notably Lower; Nasdaq Sheds 1.5 Percent

U.S. Stocks Close Notably Lower; Nasdaq Sheds 1.5 Percent

U.S. stocks tumbled on Friday and the major averages all closed notably lower with the tech-laden Nasdaq suffering a more pronounced loss as yields on 10-Year Treasury Note rose to near 8-month high.
RTTNews | 1 दिन पहले
Swiss Market Ends On Firm Note

Swiss Market Ends On Firm Note

The Switzerland market closed on a firm note on Friday, in line with markets across Europe, as investors picked up stocks from across several sectors. The benchmark SMI closed up 101.06 points or 0.88% at 11,589.34, slightly off the day's high of 11,597.29.
RTTNews | 1 दिन पहले